- Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study
-
Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto
- KMID: 1744239
- Gut Liver.
- 2009 Mar;3(1):41-47.
BACKGROUND/AIMS: Cytapheresis (CAP) is a novel strategy for ulcerative colitis (UC). However, there is insufficient data on the long-term outcome of UC patients who achieve remission by CAP. This study... -
- CITED
-
- Close
- SHARE
-
- Close
- NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
-
Sato T, Takagawa T, Kakuta Y, Nishio A, Kawai M, Kamikozuru K, Yokoyama Y, Kita Y, Miyazaki T, Iimuro M, Hida N, Hori K, Ikeuchi H, Nakamura S
- KMID: 2382376
- Intest Res.
- 2017 Jul;15(3):328-337.
- doi: 10.5217/ir.2017.15.3.328
BACKGROUND/AIMS: Recent genome-wide analyses have provided strong evidence concerning adverse events caused by thiopurine drugs such as azathioprine (AZA) and 6-mercaptopurine. The strong associations identified between NUDT15 p.Arg139Cys and thiopurine-induced... -
- CITED
-
- Close
- SHARE
-
- Close
- Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study
-
Nakamura S, Imaeda H, Nishikawa , Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A
- KMID: 2434157
- Intest Res.
- 2018 Oct;16(4):554-562.
- doi: 10.5217/ir.2018.00027
BACKGROUND/AIMS: Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity... -
- CITED
-
- Close
- SHARE
-
- Close
- Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn's Disease
-
Kato K, Fukunaga K, Kamikozuru K, Kashiwamura S, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Yokoyama Y, Kikuyama R, Miwa H, Matsumoto
- KMID: 2167272
- Gut Liver.
- 2011 Mar;5(1):37-45.
BACKGROUND/AIMS: Infliximab (IFX), an antibody to tumor necrosis factor, (TNF)-alpha has efficacy in treating Crohn's disease (CD). However, knowledge of the potential effects of IFX on patients' immune profiles is... -
- CITED
-
- Close
- SHARE
-
- Close
